Examination of Clinical Trials in Traditional Chinese Medicine: Enhancement of the Ethical Processes

International Journal of Business Society, Vol. 5, Issue 10
Zhang YanqiangTan Suyono*Ulina Karo-karo
Clinical trial registrationEthical reviewInformed consentTraditional Chinese medicine
PDFSpecial IssueDOI: 10.30566/ijo-bs/2021.special.05
5Volume
10Issue

Abstract

There is a current rise in published clinical trials relating to traditional Chinese medicine (CTM). However, the opposite execution of clinical trial registration (CTR), ethical review (ER), and informed consent (IC) relating to TCM trials are not elucidated. The current study aimed to examine CTR, ER, and IC in TCM clinical trials. TCM clinical trials selected from ten high-standard Chinese journals published in 2016 formed the study sample. Data relating to CTR, ER, and IC associated with the respective publications were obtained for further interpretation; these were acquired through two researchers’ independent reviews of the chosen papers. Six hundred fifty-nine clinical trials fulfilled the study’s inclusion criteria and were subject to analysis. Data of CTR, ER, and IC were evident in 9 (1.4%), 156 (23.7%), and 502 (72.6%) articles, respectively, and were poorly implemented. In particular, CTR and ER of TCM clinical trials should be assiduously considered by scientists, physicians, and journal editors. Education on related methodology should be made more robust.

References

[1]

K. Puri, K. Suresh, N. Gogtay, and U. Thatte, Declaration of Helsinki, 2008: implications for stakeholders in research, Journal of postgraduate medicine, vol. 55, no. 2, p. 131, 2009.

[2]

D. Harriss, A. MacSween, and G. Atkinson, Standards for ethics in sport and exercise science research: 2018 update, International journal of sports medicine, vol. 38, no. 14, pp. 1126-1131, 2017.

[3]

A. D. Gopal et al., Adherence to the International Committee of Medical Journal Editors’(ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals, Trials, vol. 19, no. 1, pp. 1-13, 2018.

[4]

D. B. Taichman et al., Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors, Annals of internal medicine, vol. 164, no. 7, pp. 505-506, 2016.

[5]

T. Wu, Y. Li, J. Li, and G. Liu, A milestone for clinical trials: establishment of a global clinical trial registration system, Chinese Clinical Trial Register, MOH Chinese Evidence-Based Medicine Centre, Chinese Cochrane Centre, INCLEN CERTC in West China Hospital, Sichuan University.(Accessed on October 2000 at http://www.chictr.org/Upload/milestone.pdf ), 2008.

[6]

Z.-X. Bian et al., Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology, Zhong xi yi jie he xue bao= Journal of Chinese integrative medicine, vol. 4, no. 2, pp. 120-129, 2006.

[7]

W. Rogers et al., Compliance with ethical standards in the reporting of donor sources and ethics review in peer-reviewed publications involving organ transplantation in China: a scoping review, BMJ Open, vol. 9, no. 2, p. e024473, 2019.

[8]

A. L. Ahlers, G. Schubert, Effective policy implementation in China’s local state, Modern China, vol. 41, no. 4, pp. 372-405, 2015.

[9]

T.-P. Fan et al., Future development of global regulations of Chinese herbal products, Journal of ethnopharmacology, vol. 140, no. 3, pp. 568-586, 2012.

[10]

T. Kobayashi, Evolution of China's aid policy. Japan Bank for International Cooperation Tokyo, 2008.

[11]

H. MacPherson, et al., Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement, The Journal of Alternative and Complementary Medicine, vol. 16, no. 10, pp. ST-1-ST-14, 2010.

[12]

H. C. Hu, The Chinese concepts of “face”, American Anthropologist, vol. 46, no. 1, pp. 45-64, 1944.

[13]

D. Xing, Y. Sun, M. Zhu, and J. Zhang, The status of IRBs/ECs, ICFs and trial registration in clinical trials of traditional Chinese medicine for stable angina, International Journal of Cardiology, vol. 174, no. 2, pp. 396-397, 2014.

[14]

L. Hooft, D. Korevaar, N. Molenaar, P. Bossuyt, and R. Scholten, Endorsement of ICMJE’s Clinical Trial Registration Policy: a survey among journal, Incidental findings; prevention is better than cure 343, p. 349, 2014.

[15]

H. Zhao, J. Zhang, F. Yang, and L. Tan, Improve the ethical review of clinical trials on traditional medicine: A cross-sectional study of clinical trial registration, ethical review, and informed consent in clinical trials of Traditional Chinese Medicine, Medicine, vol. 97, no. 47, 2018.

[16]

Y. Huo et al., Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial, JAMA, vol. 313, no. 13, pp. 1325-1335, 2015.

Article Information

Article Details
Volume & IssueVol. 5, Iss. 10
Publication DateDec 1, 2021
Authors
Zhang Yanqiang
Tan Suyono*
Ulina Karo-karo
DOI
10.30566/ijo-bs/2021.special.05
PDF Download